Journal
CELL TRANSPLANTATION
Volume 25, Issue 5, Pages 983-993Publisher
COGNIZANT COMMUNICATION CORP
DOI: 10.3727/096368916X690494
Keywords
Bone marrow mononuclear cells (BM-MNCs); Chitosan/silk fibroin scaffold; Rat sciatic nerve; Peripheral nerve repair
Funding
- Hi-Tech Research and Development Program of China (863 Program) [2012AA020502]
- National Key Basic Research Program of China (973 programs) [2014CB542202]
- National Natural Science Foundation of China [81130080, 81402447]
- Technology Project of Nantong [HS2014053]
Ask authors/readers for more resources
The therapeutic benefits of bone marrow mononuclear cells (BM-MNCs) in many diseases have been well established. To advance BM-MNC-based cell therapy into the clinic for peripheral nerve repair, in this study we developed a new design of tissue-engineered nerve grafts (TENGs), which consist of a chitosan/fibroin-based nerve scaffold and BM-MNCs serving as support cells. These TENGs were used for interpositional nerve grafting to bridge a 10-mm-long sciatic nerve defect in rats. Histological and functional assessments after nerve grafting showed that regenerative outcomes achieved by our developed TENGs were better than those achieved by chitosan/silk fibroin scaffolds and were close to those achieved by autologous nerve grafts. In addition, we used green fluorescent protein-labeled BM-MNCs to track the cell location within the chitosan/fibroin-based nerve scaffold and trace the cell fate at an early stage of sciatic nerve regeneration. The result suggested that BM-MNCs could survive at least 2 weeks after nerve grafting, thus helping to gain a preliminary mechanistic insight into the favorable effects of BM-MNCs on axonal regrowth.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available